BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced two upcoming poster presentations at the European Respiratory Society (ERS) International Congress 2026, being held September 5-9, 2026, in Barcelona, Spain.
ERS 2026 Poster Presentation Details:
Poster Title: Understanding patient perspectives on IPF clinical trial participation: Preferences, motivations, and comfort with study design
Poster Session: #246: Real-world studies: acute exacerbations and pulmonary fibrosis treatment
Presenting Author: Brittany Davis, Ph.D., Avalyn Pharma
Location: PS-34, Poster #: PA3014
Date and Time: September 7, 2026, between 8:00 a.m. – 9:30 a.m. GMT (4:00 a.m. – 5:30 a.m. EDT)
Poster Title: In silico modeling of a novel nebulized pirfenidone formulation (AP01) predicts aerosol distribution throughout the lung
Poster Session: #378: Molecular mechanisms and clinical strategies in interstitial lung diseases
Author: Michelle Palacios, Ph.D., DABT, Avalyn Pharma
Session: PS-9, Poster #: PA4377
Date and Time: September 7, 2026, between 12:30 p.m. – 2:00 p.m. GMT (8:30 a.m. – 10:00 a.m. EDT)
See the ERS online program for more details. The presentations will also be accessible on the company’s website.
About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.
Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
[email protected]
Media Contact:
Precision AQ
[email protected]